<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>partnership - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/partnership/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/partnership/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Thu, 04 Jun 2020 11:31:07 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>partnership - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/partnership/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Servier Completes the Acquisition of Symphogen </title>
		<link>https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/</link>
					<comments>https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/#respond</comments>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Thu, 04 Jun 2020 11:31:07 +0000</pubDate>
				<category><![CDATA[Immedia press]]></category>
		<category><![CDATA[a2a]]></category>
		<category><![CDATA[ambiente energia brianza]]></category>
		<category><![CDATA[GOP]]></category>
		<category><![CDATA[Nctm]]></category>
		<category><![CDATA[partnership]]></category>
		<guid isPermaLink="false">https://www.adnkronos.com/immediapress/chimica-e-farmacia/2020/06/04/servier-completes-the-acquisition-symphogen_SKipgfFLfIXdTrukOc1CyM.html</guid>

					<description><![CDATA[<p> PARIS, June 4, 2020 /PRNewswire/ -- Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S.   Symphogen will now function as Servier's antibody center of excellence across multiple therapeutic areas, including oncology. Symphogen, now...</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/">Servier Completes the Acquisition of Symphogen </a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
					<wfw:commentRss>https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>New Alliance Maps the Way in Electrophysiology </title>
		<link>https://www.newpharmaitaly.it/new-alliance-maps-the-way-in-electrophysiology/</link>
					<comments>https://www.newpharmaitaly.it/new-alliance-maps-the-way-in-electrophysiology/#respond</comments>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Wed, 20 May 2020 13:41:31 +0000</pubDate>
				<category><![CDATA[Immedia press]]></category>
		<category><![CDATA[bonellierede]]></category>
		<category><![CDATA[dlapiper]]></category>
		<category><![CDATA[partnership]]></category>
		<category><![CDATA[praticantato]]></category>
		<category><![CDATA[studio legale]]></category>
		<category><![CDATA[trainee]]></category>
		<guid isPermaLink="false">https://www.adnkronos.com/immediapress/chimica-e-farmacia/2020/05/20/new-alliance-maps-the-way-electrophysiology_5PASgIxYhtjTYOgmgNfprK.html</guid>

					<description><![CDATA[<p>A New Strategic Alliance Between BIOTRONIK, A Leader In Cardiac Rhythm Management, and Acutus Medical, Electrophysiology Innovator, Expected to Offer More Efficient and Effective Diagnosis and Treatment for Arrhythmia Patients CARLSBAD, California and BERLIN, May 20, 2020 /PRNewswire/ -- Acutus Medical and BIOTRONIK...</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/new-alliance-maps-the-way-in-electrophysiology/">New Alliance Maps the Way in Electrophysiology </a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
					<wfw:commentRss>https://www.newpharmaitaly.it/new-alliance-maps-the-way-in-electrophysiology/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>SIFI e Polpharma annunciano accordo di cross-licensing in oftalmologia</title>
		<link>https://www.newpharmaitaly.it/sifi-e-polpharma-annunciano-accordo-di-cross-licensing-in-oftalmologia/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Tue, 16 Oct 2018 14:18:38 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[cross-licensing]]></category>
		<category><![CDATA[Dry Eye]]></category>
		<category><![CDATA[Fabrizio Chines]]></category>
		<category><![CDATA[Glaucoma]]></category>
		<category><![CDATA[Markus Sieger]]></category>
		<category><![CDATA[oftalmologia]]></category>
		<category><![CDATA[partnership]]></category>
		<category><![CDATA[Polpharma]]></category>
		<category><![CDATA[SIFI]]></category>
		<guid isPermaLink="false">http://www.newpharmaitaly.it/?p=3180</guid>

					<description><![CDATA[<p>La partnership consentirà a entrambe le società di rafforzare il proprio portafoglio di prodotti oftalmici in Europa SIFI, leader italiano nello sviluppo e nella commercializzazione di terapie oftalmiche, e Polpharma, leader nel mercato farmaceutico polacco, annunciano una partnership strategica commerciale, rivolta al mercato Europeo. L&#8217;accordo consentirà di arricchire il portafoglio prodotti di entrambe le Aziende [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/sifi-e-polpharma-annunciano-accordo-di-cross-licensing-in-oftalmologia/">SIFI e Polpharma annunciano accordo di cross-licensing in oftalmologia</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
